Skip to main navigation Skip to search Skip to main content

In vitro activity of rhinacanthin analogues against drug resistant Plasmodium falciparum isolates from Northeast Thailand

  • Suwanna Chaorattanakawee
  • , Varakorn Kosaisavee
  • , Watanyu Bunsermyos
  • , Chaiyawat Aonsri
  • , Witcha Imaram
  • , Kanokon Suwannasin
  • , Chanon Kunasol
  • , Chatchadaporn Thamnurak
  • , Nonlawat Boonyalai
  • , David Saunders
  • , Arjen M. Dondorp
  • , Mathirut Mungthin
  • , Mallika Imwong*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

BACKGROUND: New anti-malarial drugs are needed urgently to address the increasing challenges of drug-resistant falciparum malaria. Two rhinacanthin analogues containing a naphthoquinone moiety resembling atovaquone showed promising in-vitro activity against a P. falciparum laboratory reference strain (K1). The anti-malarial activity of these 2 compounds was further evaluated for P. falciparum field isolates from an area of multi-drug resistance in Northeast Thailand.

METHODS: Using a pLDH enzyme-linked immunosorbent assay, four P. falciparum isolates from Northeast Thailand in 2018 were tested for in vitro sensitivity to the two synthetic rhinacanthin analogues 1 and 2 as well as established anti-malarials. Mutations in the P. falciparum cytochrome b gene, a marker for atovaquone (ATQ) resistance, were genotyped in all four field isolates as well as 100 other clinical isolates from the same area using PCR-artificial Restriction Fragment Length Polymorphisms. Pfkelch13 mutations, a marker for artemisinin (ART) resistance, were also examined in all isolates.

RESULTS: The 50% inhibitory concentrations (IC 50) of P. falciparum field isolates for rhinacanthin analogue 1 was 321.9-791.1 nM (median = 403.1 nM). Parasites were more sensitive to analogue 2: IC 50 48.6-63.3 nM (median = 52.2 nM). Similar results were obtained against P. falciparum reference laboratory strains 3D7 and W2. The ART-resistant IPC-5202 laboratory strain was more sensitive to these compounds with a median IC 50 45.9 and 3.3 nM for rhinacanthin analogues 1 and 2, respectively. The ATQ-resistant C2B laboratory strain showed high-grade resistance towards both compounds (IC 50  > 15,000 nM), and there was a strong positive correlation between the IC 50 values for these compounds and ATQ (r = 0.83-0.97, P < 0.001). There were no P. falciparum cytochrome b mutations observed in the field isolates, indicating that P. falciparum isolates from this area remained ATQ-sensitive. Pfkelch13 mutations and the ring-stage survival assay confirmed that most isolates were resistant to ART.

CONCLUSIONS: Two rhinacanthin analogues showed parasiticidal activity against multi-drug resistant P. falciparum isolates, although less potent than ATQ. Rhinacanthin analogue 2 was more potent than analogue 1, and can be a lead compound for further optimization as an anti-malarial in areas with multidrug resistance.

Original languageEnglish
Article number105
Pages (from-to)105
JournalMalaria Journal
Volume22
Issue number1
DOIs
StatePublished - 23 Mar 2023

Keywords

  • Humans
  • Antimalarials/pharmacology
  • Plasmodium falciparum
  • Atovaquone/therapeutic use
  • Thailand
  • Cytochromes b/genetics
  • Malaria, Falciparum/parasitology
  • Drug Resistance

Fingerprint

Dive into the research topics of 'In vitro activity of rhinacanthin analogues against drug resistant Plasmodium falciparum isolates from Northeast Thailand'. Together they form a unique fingerprint.

Cite this